| Description | SGN-2FF is an oral fucosyltransferase inhibitor with antitumor activity. |
| In vitro | SGN-2FF 是一种抑制果糖化的化合物，通过耗竭果糖化底物GDP-果糖来抑制细胞内的果糖化。SGN-2FF 抑制果糖转移酶，诱导包含抗体在内的果糖化糖蛋白的产生。SGN-2FF以抗原依赖的方式激活人类T细胞。 |
| In vivo | 在多个小鼠肿瘤模型中，SGN-2FF显示出抗肿瘤活性。SGN-2FF显著延缓了肿瘤生长。在同源小鼠模型中，SGN-2FF增强了淋巴瘤疫苗的保护效果。 |
| molecular weight | 166.15 |
| Molecular formula | C6H11FO4 |
| CAS | 2089647-47-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | H2O: 35 mg/mL (210.65 mM), Sonication is recommended. DMSO: 50 mg/mL (300.93 mM), Sonication is recommended. |
| References | 1. Stephen C. Alley, et al. Abstract DDT02-02: SGN-2FF: A novel small molecule inhibitor of fucosylation with preclinical antitumor activity through multiple immune mechanisms. Cancer Res 2017;77(13 Suppl). |
| Citations | 1. Pan Q, Xie Y, Zhang Y, et al.EGFR core fucosylation, induced by hepatitis C virus, promotes TRIM40-mediated-RIG-I ubiquitination and suppresses interferon-I antiviral defenses.Nature Communications.2024, 15(1): 652. |